Cardiff Oncology Sets UBS Biopharma Conference Appearance 2026

Key Points

• Cardiff Oncology, Inc. (Nasdaq: CRDF) is set to participate in and conduct one-on-one meetings with investors at the UBS Global Biopharma Conference, which is slated to take place from 16–17 November 2026.
• Mani Mohindru, Chief Executive Officer, PhD, will conduct a fireside chat session on 16 November 2026 at 2:40 PM GMT.
• The conference is taking place in London from 16-17 November 2026.
• Interested parties can register for the webcast of this event through the Events page on Cardiff Oncology’s official website.
• Cardiff Oncology is a clinical stage biotechnology company developing cancer treatments using PLK1 inhibition technology.
• Its lead drug candidate, onvansertib, is an oral PLK1 inhibitor and is being investigated in a Phase 2 trial for first-line RAS-mutated metastatic colorectal cancer (mCRC).
• Also, onvansertib is under investigation in other cancers driven by PLK1 through investigator-initiated trials.
• Previously, it had announced that its Phase 2 CRDF-004 trial had selected 30 mg onvansertib plus FOLFIRI/bevacizumab for advancement towards a registrational study.
• The press release was issued via GlobeNewswire on 3 November 2026 and was also covered by KXAN and others.

Cardiff (Wales Times) November 03, 2026 — uk/local/cardiff/">Cardiff Oncology, Inc. has announced that its management will present at and participate in investor meetings during the UBS Global Biopharma Conference later this month, providing a further opportunity for the clinical-stage cancer-drug developer to engage with institutional investors and industry participants. As reported by GlobeNewswire, the company said its management will deliver a presentation and join 1×1 investor meetings at the conference, which runs on 16–17 November 2026.

The San Diego-based biotechnology company, which trades on Nasdaq under the ticker CRDF, focuses on developing therapies that use PLK1 inhibition across a range of cancers. Its announcement did not disclose any new clinical data, regulatory decision, financing, or partnership; instead, it set out the company’s participation arrangements for the UBS event.

What Will Cardiff Oncology Present at the Conference?

Cardiff Oncology said that Mani Mohindru, PhD, the company’s President and Chief Executive Officer, will take part in a fireside chat at the UBS Global Biopharma Conference. According to the company’s announcement, the session is scheduled for 16 November 2026 at 2:40 PM GMT.

The company also said that management will participate in one-to-one investor meetings during the two-day conference. Such meetings commonly allow company leadership to discuss corporate strategy, clinical programmes and business developments directly with investors, although Cardiff Oncology’s announcement did not specify which topics would be discussed in those private sessions.

Interested parties have been directed to the Events section of Cardiff Oncology’s website to register for and access the live webcast. The company said a replay of the presentation will be available after the session concludes.

Where Is the UBS Global Biopharma Conference Being Held?

The UBS Global Biopharma Conference is scheduled to take place in London from 16–17 November 2026, according to UBS’s healthcare-focused event information. Cardiff Oncology’s announcement confirms that its participation will span both dates of the conference.

The event brings together biopharmaceutical companies and investors, with scheduled presentations and investor meetings. Other companies have also listed their participation in the same conference, including Gilead Sciences, Relay Therapeutics and Disc Medicine, according to their respective investor-relations pages.

Why Is Cardiff Oncology Attending the Investor Conference?

Cardiff Oncology described the conference participation as an opportunity for management to present and meet investors. The company’s announcement did not state that a new corporate announcement would be made at the event.

The appearance comes at a time when the company’s principal clinical programme, onvansertib, remains under evaluation in first-line RAS-mutated metastatic colorectal cancer. In its announcement, Cardiff Oncology said onvansertib is a highly specific, oral PLK1 inhibitor currently being assessed in a Phase 2 trial for that indication, which it described as a large and underserved patient population with high unmet need.

What Is Onvansertib and PLK1 Inhibition?

Onvansertib is Cardiff Oncology’s lead asset. The company describes it as a highly specific, oral inhibitor of PLK1, a target it characterises as validated in oncology.

PLK1 inhibition is the scientific approach underpinning Cardiff Oncology’s development strategy. In its corporate description, the company says it aims to target tumour vulnerabilities, overcome treatment resistance and improve clinical outcomes for patients.

Beyond metastatic colorectal cancer, Cardiff Oncology said onvansertib is being investigated in other PLK1-driven cancers through ongoing investigator-initiated trials. The company also stated that the drug has shown robust single-agent clinical activity in hard-to-treat tumours.

What Has Cardiff Oncology Previously Reported About Its Lead Trial?

Cardiff Oncology’s latest conference announcement does not include updated trial results. However, the company’s earlier disclosures provide context for the programme likely to be of interest to investors.

In a September 2026 press release filed with the U.S. Securities and Exchange Commission, Cardiff Oncology said that, in a randomised Phase 2 trial, onvansertib in combination with FOLFIRI/bevacizumab demonstrated dose-dependent improvements in overall response rate and progression-free survival compared with standard-of-care alone. The company said it selected the 30 mg dose of onvansertib in combination with FOLFIRI/bevacizumab for advancement into a registrational trial in first-line RAS-mutated mCRC.

As reported in Cardiff Oncology’s June 2026 announcement, the selected regimen demonstrated what the company described as deep and durable tumour shrinkage, including clinically meaningful improvements in overall response rate and progression-free survival compared with standard-of-care alone, with no additive adverse events. The company also said it had aligned with the U.S. Food and Drug Administration on the design of a registrational Phase 3 trial.

In its second-quarter 2026 business update, Cardiff Oncology reported that the 30 mg onvansertib plus FOLFIRI/bevacizumab arm achieved a confirmed objective response rate of 72.2%, compared with 42.1% for FOLFIRI/bevacizumab alone. The company characterised this as a 30% improvement in response rate over standard of care.

Does the Announcement Include New Clinical or Financial Information?

No. The 3 November announcement concerns conference participation only. It does not report new trial data, a regulatory filing, an approval, a financing, a partnership or a change to the company’s clinical-development timetable.

The release identifies Candice Masse of Astr Partners as the investor contact and Amy Bonanno of Lyra Strategic Advisory as the media contact. It also directs readers to Cardiff Oncology’s website for further company information.

Who Reported the Announcement?

The announcement was issued through GlobeNewswire on 3 November 2026 under the headline “Cardiff Oncology to Participate in the UBS Global Biopharma Conference”. The same release was subsequently carried by KXAN in its business press-release section, which credited the news to GlobeNewswire and dated it 3 November 2026 at 7:00 AM ET.

The company’s release did not attribute any quotation to an executive. It identified Dr Mohindru as the fireside-chat presenter but did not include a direct statement from him about the conference or the company’s clinical programme.

Background of the Development

Cardiff Oncology is a clinical-stage biotechnology company working on cancer treatments centred on PLK1 inhibition. Its lead candidate, onvansertib, is an oral PLK1 inhibitor under evaluation in first-line RAS-mutated metastatic colorectal cancer, according to the company’s 3 November announcement.

The company’s CRDF-004 trial has been a central part of its development narrative. Cardiff Oncology previously described CRDF-004 as a randomised, controlled, dose-finding Phase 2 trial evaluating onvansertib in combination with standard-of-care regimens—FOLFIRI/bevacizumab or FOLFOX/bevacizumab—in patients with first-line RAS-mutated metastatic colorectal cancer.

In June 2026, the company announced positive results from that trial at the American Society of Clinical Oncology Annual Meeting. It said the selected 30 mg onvansertib plus FOLFIRI/bevacizumab regimen showed improvements in response rate and progression-free survival relative to standard-of-care alone, and that it had aligned with the FDA on key design elements for a planned registrational Phase 3 trial.

The company later reported that the planned Phase 3 trial is expected to evaluate 30 mg onvansertib in combination with FOLFIRI/bevacizumab against standard-of-care FOLFIRI/bevacizumab as first-line therapy in patients with RAS-mutated mCRC. These earlier disclosures provide the clinical backdrop to the company’s investor-conference appearance, although the new announcement itself does not update that programme.

Prediction: How May This Affect Investors and Patients?

For investors, the announcement is primarily an event-scheduling update rather than a material clinical or financial development. Its likely near-term relevance lies in giving shareholders and prospective investors a fixed date to hear management discuss the company’s strategy, with the fireside chat and webcast providing a public window into Cardiff Oncology’s priorities.

Investors following CRDF may focus on whether management provides further detail on the planned registrational Phase 3 programme for onvansertib, the status of the ongoing Phase 2 trial, or the broader development strategy across other PLK1-driven cancers. However, the company has not said that any new data or corporate update will be presented at the conference, so no such outcome should be assumed from the announcement alone.

For patients and patient advocates, the development does not change access to onvansertib or alter the evidence base for treatment decisions. The company’s earlier disclosures indicate that onvansertib remains in clinical development rather than approved routine care, and its Phase 2 programme in first-line RAS-mutated mCRC is still ongoing.

If Cardiff Oncology advances its proposed registrational Phase 3 trial as previously described, future results would be the more significant point for patients with RAS-mutated metastatic colorectal cancer. Until then, the UBS conference appearance is best understood as a routine investor-engagement step for a clinical-stage biotechnology company preparing to explain its development plans to the investment community.